News

In clinical trials evaluating new therapies for lymphoma, the disease assessments are primarily driven by the Lugano Classification 2014 and rely heavily on PET avidity and changes in measurable disease. These objective measures are critical for standardizing evaluations and ensuring…   Read More

Immunotherapy has transformed cancer treatment by harnessing the body’s natural defenses to target and destroy cancer cells. However, evaluating its effectiveness presents unique challenges. Imaging is crucial—not only for monitoring tumor response and detecting distinctive patterns like pseudoprogression, but also…   Read More

Radiopharmaceutical therapies (RPTs) are transforming cancer treatment by combining radiation with targeted drug delivery. These therapies require a delicate balance between effectiveness and safety, especially considering the unique long-term risks of radiation exposure. The FDA recently released a draft guidance…   Read More

Gliomas are the most common type of malignant primary brain tumor. Imaging is crucial in diagnosing gliomas and evaluating treatment responses. Proper application and customization of the RANO and RAPNO criteria for each unique clinical trial, including criteria clarifications and…   Read More

Imaging is vital for diagnosing, staging, and monitoring multiple myeloma (MM) in clinical trials. Common imaging methods include Whole-Body Low-Dose CT, ideal for initial MM-related lytic bone lesion assessment; MRI, the gold standard for detecting bone marrow involvement; and 18F-FDG…   Read More

Colorectal cancer (CRC) is the third most frequent cancer diagnosed in the world, and the second most frequent cause of death related to cancer. Imaging has a critical role in diagnosis, determining stage of the disease, selecting treatment strategies, and…   Read More

Medical imaging is pivotal in clinical trials for gastric cancer, where precise staging and response evaluation are essential. Imaging technologies like CT, MRI, and PET are integrated into clinical trials, typically using Response Evaluation Criteria in Solid Tumors (RECIST). These…   Read More

The assessment of peritoneal metastasis in ovarian cancer is a critical challenge in clinical trials. Inaccurate evaluations can lead to significant discrepancies in treatment responses and patient management. Recent discussions, including insights from Dr. M. Sharma and colleagues at ECR25,…   Read More

In the rapidly evolving landscape of clinical trials, maintaining data integrity and minimizing bias while performing BICR (Blinded Independent Central Review) is paramount. The automation of reviewer performance monitoring through advanced platforms, complemented by artificial intelligence (AI), is revolutionizing the…   Read More